Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2025 Earnings Call Transcript
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $1.03 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.11 per share a year ago.
Arcturus Therapeutics: Two Catalysts, One Runway, And A Stock Priced For Failure
Arcturus Therapeutics now centers on ARCT-032 (cystic fibrosis) and ARCT-810 (OTC deficiency), with Covid assets as secondary cash support. ARCT is priced as a busted biotech with optionality; cash runway extends to 2028, but clinical and regulatory risks remain significant. ARCT-032's 12-week trial and ARCT-810's FDA alignment are key re-rating catalysts; both programs face pivotal data and regulatory endpoints.
ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know
Arcturus Therapeutics' stock slides 59%, primarily due to mixed interim results from the phase II study of its investigational inhaled cystic fibrosis therapy, ARCT-032.
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 Earnings Call Transcript
Arcturus Therapeutics Holdings Inc. ( ARCT ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Neda Safarzadeh - Vice President and Head of IR/PR & Marketing Joseph Payne - Founder, President, CEO & Director Andrew Sassine - CFO & Director Conference Call Participants Yasmeen Rahimi - Piper Sandler & Co., Research Division Jake Batchelder - William Blair & Company L.L.C., Research Division Boran Wang - Guggenheim Securities, LLC, Research Division Angela Qian - Canaccord Genuity Corp., Research Division Kuan-Hung Lin - Wells Fargo Securities, LLC, Research Division Joohwan Kim Thomas Shrader - BTIG, LLC, Research Division Yale Jen - Laidlaw & Company (UK) Ltd.
Arcturus Therapeutics (ARCT) Reports Q3 Loss, Beats Revenue Estimates
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $1.25. This compares to a loss of $0.26 per share a year ago.
Earnings Preview: Arcturus Therapeutics (ARCT) Q3 Earnings Expected to Decline
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcturus Therapeutics (ARCT) Moves 7.7% Higher: Will This Strength Last?
Arcturus Therapeutics (ARCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
4 Stocks With Recent Price Strength to Maximize Your Gains
FLUX, AUGO, ARCT and STRL are showing notable price strength amid a volatile market.
Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 Earnings Conference Call Transcript
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q2 2025 Earnings Conference August 11, 2025 4:30 PM ET Company Participants Andrew H. Sassine - CFO & Director Joseph E.
Arcturus Therapeutics (ARCT) Reports Q2 Loss, Tops Revenue Estimates
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to a loss of $0.64 per share a year ago.
Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet
The mean of analysts' price targets for Arcturus Therapeutics (ARCT) points to a 371.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
